and Italian patients. 8 As for BKV in paediatric HC patients, few data exist. In this study, we investigated prospectively a cohort of paediatric and adolescent patients for both BK and Ad viruria during HSCT.
Twenty-four consecutive unselected paediatric/adolescent patients undergoing HSCT were studied (Table 1) . None had a history of AdV or BKV infection. Details of the prophylaxis against HC, GVHD, and herpes simplex virus and cytomegalovirus infections have been described. 2, 4 Spot urine samples were collected at weekly intervals to six weeks post-HSCT. Details of Q-PCR for urinary BKV and AdV loads were reported previously. 4 Standard curves for BKV was constructed by a serial dilution of BKV pB-VP1 from 0.5 fg to 50 pg. For AdV, to increase the range of Q-PCR for measuring even smaller quantities of AdV, standard curves were constructed using AdV pB-hexon at 100-fold less serial dilutions (0.005-500 fg).
The median age of the 24 patients was 6.5 years (Table 1) . Post-engraftment HC developed in 2/15 cases of allogeneic HSCT, and in none of nine cases of autologous HSCT (P ¼ 0.25, w 2 -test). Both HC patients were in the adolescent or young adult age group (14 and 22 years old).
Quantification of BK viruria was performed serially in all 24 cases, at a median of seven (4-12) samples per patient. Eleven patients had consistently quantifiable BK viruria, detectable at a median of 4 (2-11) separate time points. BK viruria peaked at a median of 21 (7-56) days post-HSCT, with a median peak level at 1.6 Â 10 8 (9.9 Â 10 4 À3.6 Â 10 9 ) copies/ml. Two of these patients developed post-engraftment HC. Both patients had BK viruria peaking (on days 18 and 32) before the onset of HC (on days 24 and 70). Patients with BK viruria were significantly older than those without (median age: 11 versus 4 years, P ¼ 0.045) ( Table 2 ). With 5 years as a cutoff, younger patients were significantly less likely to have BK viruria as compared with older ones (1/8 versus 10/16, P ¼ 0.02). Other factors, including the source of HSC, CMV serology and GVHD, were comparable. None of the urine samples contained detectable AdV, even with the Q-PCR modified to detect miniscule amounts of the virus.
To date, this is the first study examining patients younger than 8 years for BK and Ad viruria after HSCT. The results increase our knowledge of BKV reactivation and HC post-HSCT in paediatric/adolescent patients. BKV reactivation has rarely been discussed or emphasized in paediatric and adolescent patients post-HSCT. We showed that the pattern of BKV reactivation in paediatric/adolescent patients was comparable to adults. Furthermore, postengraftment HC was found only in patients showing BKV Graft-versus-host disease 4 Post-engraftment haemorrhagic cystitis 2 (grade III and IV) reactivation, with the onset of HC characteristically lagging behind the peaking of BK viruria. These results offer robust support that, similar to adults, BKV reactivation is of pathogenetic significance in HC complicating HSCT in paediatric/adolescent patients. However, BK viruria was only found in less than half of the patients studied, as opposed to the almost universal presence of BK viruria in adult patients. We found that this difference was due to a much lower incidence of BK viruria in young patients (o5 years old). To our knowledge, an age-dependent increase in urinary BKV reactivation has not been reported. This was because in previous studies where paediatric patients were investigated, none contained patients younger than 8-9 years, so that the effect of age on the incidence of BKV reactivation could not be examined. Recent studies have shown that the sero-prevalence of BKV was low at 20% in children 1-3 years old. The prevalence increased gradually to 60% in children 3-5 years old, and reached 80% or more in those older than 5 years. 9 Therefore, the absence of BK viruria in our young patients might be due to the fact that primary BKV infection had not yet occurred. As a result, there was no BKV viruria detectable even during immunosuppression. This agerelated difference in BK viruria may explain why urinary BKV reactivation is almost universal in adult patients after HSCT, as virtually all adults have past BKV infections. As pre-HSCT BKV serologic data are not available for our cohort, this proposition will have to be validated by future studies.
We were unable to find Ad viruria by Q-PCR in any of our patients, including two patients who developed postengraftment HC. In contrast to BKV, AdV infections are endemic in paediatric populations, with the infection peaking in infants and children between the ages of 6 months and 5 years. 10 Reactivation of AdV, as defined by PCR-quantifiable Ad viremia, appears to be frequent after HSCT in paediatric patients. 10 Results in the current study, however, suggest that in our paediatric populations, reactivation of AdV in the urinary tract was a rare phenomenon. Other recent studies have also failed to identify AdV as an important putative agent in HC post-HSCT. 4, 8 Finally, an attractive hypothesis is that the relatively low frequency of BKV reactivation among paediatric patients may result in fewer HC. As the two cases of HC in the current series occurred in adolescent patients, our results appear to support this proposition. Given that past BKV infection may not have occurred in all patients, the question remains whether detectable BK viruria in some paediatric patients represents reactivation, or primary infection from contacts or blood products. Moreover, the observation of BK viruria with a virologic profile comparable to adults in a significant number of paediatric patients, and the association of BK viruria with post-engraftment HC, suggest that strategies similar to adults for the prevention of BKV reactivation may also be useful in paediatric patients. 
